Inspections, Compliance, Enforcement, and Criminal Investigations
Diagnostic Clinic of Longview, P.A. 04-Jun-02
7920 Elmbrook Drive
Dallas, TX 75247-4982
June 4, 2002
RETURN RECEIPT REQUESTED
Diagnostic Clinic of Longview, P.A.
707 Hollybrook Drive
Longview, TX 75605
Dear Mr. Ratay:
Re: Inspection ID - 1687160007
We are writing to you because on May 14, 2002, a representative of the State of Texas, acting on behalf of the Food and Drug Administration (FDA), inspected your facility. This inspection revealed a serious regulatory problem involving the mammography at your facility. Under the Mammography Quality Standards Act of 1992 (MQSA or "the Act"), 42 U.S.C. 263b, and the Quality Standards for Mammography, set forth in Title 21, Code of Federal Regulations (CFR), Part 900.12, your facility must meet specific requirements for mammography. These requirements help protect the health of women by assuring that a facility can perform quality mammography. The inspection revealed the following violations at your facility:
Level 1: The system to communicate results is not adequate for site because:
-There is no system in place to provide timely medical reports.
-There is no system in place to provide timely lay summaries.
-There is no system in place to communicate serious or highly suggestive cases as soon as possible (see 21 CFR 900.12(c)(2)& (c)(3)).
Level 2 Repeat: Phantom QC records were missing for at least two weeks but less than four weeks for unit 3, General Electric Co. (GE Medical Systems), 800, room 2 (see 21 CFR 900.12(e)(2)).
Level 2 Repeat: Medical audit and outcome analysis was not done for the facility as a whole (see 21 CFR 900.12(f)(1)).
Level 2 Repeat: Medical audit and outcome analysis was not done separately for each individual (see 21 CFR 900.12(f)(1)).
Level 2 Repeat: Medical audit and outcome analysis was not performed annually (see 21 CFR 900.12(f)(2)).
The specific problems noted above appeared on your MQSA Facility Inspection Report, which was issued to your facility at the close of the inspection. A Level 1 or repeated Level 2 finding indicates that the inspector found one or more deviations from MQSA standards that may seriously compromise the quality of mammography services offered by the facility.
Because these conditions may be symptomatic of serious underlying problems that could compromise the quality of mammography at your facility, it represents a serious violation of the law which may result in FDA imposing statutory sanctions without further notice to you. These sanctions include, but are not limited to, placing your facility under a Directed Plan of Correction, and/or charging your facility for the cost of on-site monitoring. Failure to correct these violations promptly could also cause FDA to seek civil money penalties up to $10,000 for each failure to substantially comply with, or each day of failure to substantially comply with the MQSA Standards, suspension or revocation of your facility?s FDA certificate, or obtaining a court injunction against further mammography (see sections 263b(h) through (j) of the Act).
It is necessary for you to act on this matter immediately. Please explain to this office in writing within fifteen (15) working days from the date you received this letter:
1. the specific steps you have taken to correct all of the violations noted in this letter;
2. each step your facility is taking to prevent the recurrence of similar violations;
3. equipment settings (including technique factors), raw test data, and calculated final results, where appropriate; and
4. sample records that demonstrate proper record keeping procedures, if the findings relate to quality control or other records (Note: Patient names or identification should be deleted from any copies submitted).Please submit your response to:
Deborah M. McGee, Radiation Specialist
Food and Drug Administration
7920 Elmbrook Drive, Suite 102
Dallas, TX 75247-4982
Finally, you should understand that there are many FDA requirements pertaining to mammography. This letter pertains only to certain findings of your inspection and does not necessarily address other obligations you have under the law, including, but not limited to, correcting the other violations cited on your MQSA Facility Inspection Report. You may obtain general information about all of FDA?s requirements for mammography facilities by contacting the Mammography Quality Assurance Program, Food and Drug Administration, P.O. Box 6057, Columbia, MD 21045-6057 (1-800-838-7715) or through the Internet at http://www.fda.gov/cdrh/mammography/index.html.
If you have more specific questions about mammography facility requirements, or about the content of this letter, please feel free to contact Deborah M. McGee at (214) 655-8100, ext. 138.
Darryl Brown for Gary L. Pierce
Regional Food and Drug Director